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Abstract
Introduction: T-cell lymphoma invasion and metastasis-inducing protein (Tiam1) is an Ras-related C3 botulinum
toxin substrate (Rac)-specific guanine nucleotide exchange factor that was isolated based on its ability to induce a
metastatic phenotype. In polarized migrating keratinocytes, Tiam1 is found at the leading edge, where it
cooperates with the protease-activated receptor 1 (Par1) complex to establish front-to-rear polarity. Although a
positive correlation has been observed between Tiam1 expression and tumor grade in a variety of human
malignancies, including breast, its role in breast cancer cells has not yet been examined.
Methods: Tiam1 expression and Rac activity were examined in a panel of human breast cancer cell lines that
exhibit different degrees of cell motility. The contribution of Tiam1 to cell motility was directly examined by using
transwell motility and wound-healing assays.
Results: Although we observed a striking, positive correlation between Tiam1 expression and cell motility in the
panel of breast cancer cell lines, we did not observe a correlation between Tiam1 expression and overall levels of
Rac activity. Consistent with this, small interfering ribonucleic acid (siRNA)-mediated suppression of Tiam1
expression limits the motility of cell lines in which Tiam1 expression is high (MDA-MB-231 and MDA-MB-453) but
does not substantially alter the overall levels of activated Rac. Tiam1 overexpression is also not sufficient to increase
the motility of more poorly motile cells (T-47D) or to increase Rac activity. Immunofluorescence and cellular
fractionations indicate that Tiam1 is found predominantly in the Golgi of breast cancer cells, and in the latter case,
Tiam1 was shown to co-fractionate with a limited pool of Rac1. Consistent with this Golgi localization, Tiam1
supports cell motility and Golgi reorientation in response to serum in a wound-healing assay using MDA-MB-231
and MDA-MB-435S cells.
Conclusions: Tiam1 expression correlates with cell motility in human breast cancer cells and is required to support
the motile phenotype. Localization of endogenous Tiam1 to the Golgi, and its demonstrated role in Golgi
reorientation, suggest that it may support motility through a mechanism that is discrete from its known function in
leading-edge dynamics.
Introduction
Directed cell migration is a regulated process that
occurs during embryonic development [1], wound heal-
ing [2], bone remodeling [3], angiogenesis [4], and the
immune response [5], and is observed under pathologic
conditions such as atherosclerosis [6], tumor cell moti-
lity, and metastasis [7]. Features of the polarized, motile
cell include the formation of filopodia and lamellipodia
at the leading edge, stabilization and localized capture of
microtubules at the leading edge, and reorientation of
the microtubule organizing center and Golgi complex
toward the direction of migration [8]. The reorientation
of the Golgi and microtubules may facilitate the traffick-
ing of the protein and lipid components that would be
required at the leading edge for membrane remodeling
and protrusion to occur [9,10]. Although the cellular
activities that are required to support motility were first
identified and described in noncancer cells [11],
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subsequent studies have established that cancer cells, for
the most part, use the equivalent molecular mechanisms
[12,13].
Members of the Rho family of small GTPases have
emerged as key regulators of cell polarity and motility
[14,15]. Rho proteins function as binary switches cycling
between an active GTP-bound state and an inactive
GDP-bound state. The steady-state level of Rho-GTP in
cells is determined by the actions of three families of
regulatory molecules. Guanine nucleotide exchange fac-
tors (GEFs) activate RhoGTPases by catalyzing the
exchange of GDP for GTP [16]; RhoGTPase activating
proteins inhibit Rho function by stimulating the intrinsic
rate of GTP hydrolysis [17]; whereas guanine nucleotide
dissociation inhibitors sequester Rho-GDP in an inactive
state [18]. Binding to GTP induces a conformational
change in a Rho protein, which allows binding and acti-
vation of downstream signaling molecules [19]. The Rho
family members RhoA, Rac1, and Cdc42 have been
identified as key regulators of cell motility, initially
based on their ability to regulate the actin cytoskeleton
[9]. Subsequent studies revealed an important role for
these three Rho family members in virtually all aspects
of the motile phenotype, including actin reorganization,
microtubule stabilization and capture, centrosome reor-
ientation, and vesicle trafficking from the Golgi [8].
Tiam1 is a Rac-specific GEF [20] that was originally
identified in a screen for proteins whose overexpression
can cause an invasive phenotype in T-lymphoma cells
[21]. Subsequent studies have identified roles for Tiam1
in the regulation of apical-basal polarity in epithelial
cells, neurite growth and differentiation, and cell moti-
lity [22,23]. Each of these activities involves a regulatory
interaction between Tiam1 and the Par polarity complex
[22]. Thus, in polarized migrating keratinocytes, Tiam1
associates with Par3 and Protein kinase C-ζ at the lead-
ing edge, where it cooperates with the Par complex to
establish front-to-rear polarity by promoting the stabili-
zation of the microtubule network [24]. Although these
results appear to be in conflict with earlier studies indi-
cating that Tiam1 promotes cell adhesion in contacting
keratinocytes [25], it has been proposed that when cell-
to-cell contacts are present, the function of Tiam1 is to
support apical-basal polarity, but when such contacts
are absent, such as in migrating keratinocytes, Tiam1
promotes cell motility by stabilizing front-to-rear polar-
ity [24].
Although most evidence supports a role for Tiam1 in
cancer progression, it appears to have both growth-
suppressive and growth-promoting functions, depending
on the tumor type examined. Like many Rho-specific
GEF family members, a derivative of Tiam1 that lacks
the amino terminus has oncogenic activity when overex-
pressed in NIH 3T3 cells [26,27]. Consistent with this
oncogenic activity, an examination of 40 human tumor
cell lines including neuroblastomas, melanomas, hema-
topoietic tumors, lung carcinomas, colon carcinomas,
and breast carcinomas revealed that Tiam1 was
expressed in virtually all the cell lines [28]. A correlation
between Tiam1 expression and tumor grade has been
observed in breast carcinoma [29], nasopharyngeal carci-
noma [30], hepatocellular carcinoma [31], retinoblas-
toma [32], and prostate cancer [33]. In tumor types in
which elevated expression is observed, Tiam1 may sup-
port cancer progression by regulating motility and
metastasis. The metastatic potential of eight colon
tumor cell lines positively correlates with Tiam1 expres-
sion [34], and overexpression of Tiam1 contributes to
the metastatic potential of colon cancer cells [35,36].
Tiam1 protein expression also correlates with migration
capacity in breast tumor cell lines [23], and a close cor-
relation has been observed between increased Tiam1
expression and tumor grade [29]. In mice, Tiam1
expression has been shown to be necessary for Neu-
induced, but not Myc-induced, mammary tumor forma-
tion [37].
Not all studies support a role for Tiam1 as an onco-
gene. Thus, in renal cell carcinoma [38], breast carci-
noma [39], and gastric cancer [40], an inverse
correlation has also been observed between Tiam1
expression and invasive potential, and Tiam1 expression
in renal carcinoma cells inhibits migration by promoting
E-cadherin-mediated adhesion [38]. Studies using mouse
models suggest that Tiam1 may function as both an
oncogene and tumor suppressor during tumor progres-
sion. Thus, Tiam1-null mice are resistant to Ras- and
adenomatous polyposis coli (APC)-induced tumors, but
the tumors that do form are more likely to progress
[41,42]. Evidence suggests that Tiam1 supports Ras-
induced tumorigenesis by inhibiting apoptosis and pro-
moting proliferation, but that the tumors that do grow
progress more rapidly because of the normal role of
Tiam1 in maintaining cell-to-cell interactions [42]. A
similar dual contribution by Tiam1 to tumor progres-
sion has been proposed for APC-induced tumors [41].
Collectively, these observations suggest that the contri-
bution of Tiam1 to tumorigenesis is dependent on the
tumor type, the degree of tumor progression, and the
signaling context. Thus, during early stages of tumor
progression, suppression of Tiam1 expression may be
necessary to disrupt cell-to-cell adhesions and support
epithelial-mesenchymal transition [43]. However, as a
limited population of tumor cells acquire an invasive
phenotype, Tiam1 expression may be restored to sup-
port invasion or polarized motility.
Although it was previously reported that Tiam1
expression is elevated in human breast cancer cell lines
[23], the activity of Tiam1 in these cells is unknown. In
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the current study, we observed a close correlation
between Tiam1 expression and motility in a panel of
human breast tumor cell lines. Tiam1 expression is
required to support cell movement in the more-motile
cell lines, but is not sufficient to induce motility in a
less-invasive cell line. Both Tiam1 and Rac1 localize to
the Golgi apparatus in the more-motile cell lines, and
both are required to support serum-induced Golgi reor-
ientation in a wound-healing assay. These results estab-
lish a role for Tiam1 in supporting breast tumor cell
motility and suggest that this role may be independent
of its contributions to leading-edge dynamics.
Materials and methods
Molecular constructs
pCDNA3-Tiam1 and pCDNA3-Rac61L(HA) encode
full-length human Tiam1 and a hemagglutinin (HA)-
epitope tagged, constitutively activated mutant of Rac1,
respectively.
Cell culture and transfection
All cell lines used for this analysis were obtained from
American Type Culture Collection. The MDA-MB-231,
MDA-MB-435 S, MDA-MB-453, and ZR-75-1 cell lines
were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% Fetal Bovine Serum
(FBS; Gemini Bio-Products), 100 U/ml penicillin/strep-
tomycin (Cellgro MediaTech), 2 mM L-glutamine (Cell-
gro MediaTech), and 1 mM sodium pyruvate (Cellgro
MediaTech). T-47 D cells were cultured in Roswell Park
Memorial Institute 1640 Medium supplemented with
10% FBS, 100 U/ml penicillin/streptomycin, and 2 mM
L-glutamine. MCF-10A cells were cultured in 50%
DMEM/50% Hams F12 Medium supplemented with 5%
horse serum (Sigma-Aldrich), 0.5 mg/ml hydrocortisone
(Sigma-Aldrich), 10 μg/ml human epidermal growth fac-
tor (Sigma-Aldrich),100 ng/ml Cholera toxin (Sigma-
Aldrich), 5 mg/ml insulin (Invitrogen), and 50 U/ml
penicillin/streptomycin. To establish stable cell lines,
cells were transfected with Lipofectamine 2000 reagent
(Invitrogen) according to the manufacturer’s recom-
mended protocol and then selected in growth medium
supplemented with Geneticin (400 ng/ml, Invitrogen).
For each transfection, more than 200 drug-resistant
colonies were combined to generate a polyclonal stable
cell line, and three independent cell lines were generated
and tested for each construct.
Reagents
Brefeldin A (BFA: 10 μg/ml; Invitrogen) was added to
cells in serum-starved media (0.5% serum) for 30 min,
and then cells were allowed a 3-hour recovery period
before staining or transwell motility assays. The Rac1
inhibitor (50 μM NSC23766; Calbiochem) was added
under serum-starved conditions for 12 hours and then
was maintained through the course of the Golgi-
reorientation assays. Antibodies used for Western blots
and immunofluorescence included anti-Tiam1 (Santa
Cruz, sc-872), anti-Vav (Santa Cruz, sc-132), anti-
Cdc42 (BD Transduction Laboratories), anti-Rac1 (BD
Transduction Laboratories, and Santa Cruz, sc-95),
anti-a tubulin (Sigma-Aldrich), anti-a actinin (Sigma-
Aldrich), anti-HA (BAbCO), anti-GM130 (BD Trans-
duction Laboratories), and anti-Rho A (Santa Cruz,
sc-418). Western blot analysis was performed as pre-
viously described [44]. A blocking peptide for the
Tiam1 antibody (Santa Cruz, sc872P) was used to vali-
date the specificity of the antibody according to the
manufacturer’s protocols.
Cdc42 and Rac1 activation assays
Affinity purification assays to measure the levels of
endogenous GTP-bound Rac1 and Cdc42 were per-
formed by using the Cdc42- and Rac-binding domain of
p21 activated kinase (GST-PAK), as previously described
[45].
Transfection of siRNA
siRNAs specific for Tiam1 or controls (Santa Cruz) were
transiently transfected into cells by using SiLentFectTM
lipid reagent (Bio-Rad), according to the manufacturer’s
protocols. The minimal concentration of siRNAs that
could consistently reduce total Tiam1 protein expression
by greater than 75% was determined with Western blot
analysis. The viability of the transfected cells was con-
firmed with the trypan blue exclusion method.
Motility assays
Transwell motility assays were performed as previously
described [46]. Subconfluent cells were detached with
0.05% trypsin, and 2.5 × 104 cells were loaded into the
top chamber of transwells coated from the underside
with collagen I, and then allowed to migrate. Cells that
migrated to the underside of the membranes were fixed
and stained with Diff-Quik (Dade Behring) and counted.
All experiments were performed in triplicate, and eight
to 12 fields of view for each transwell were counted.
The average number of cells per field was then calcu-
lated. For wound-healing assays, confluent cells were
serum starved overnight (0.5% serum). The following
day, cells were wounded with a sterile 200-ml pipette tip
and then cultured in complete media (10% serum).
Designated points on the wound were selected randomly
and photographed at indicated intervals to observe dif-
ferences in wound closure. All experiments were per-
formed in triplicate. Where indicated, cells were
transiently transfected with siRNAs 48 hours before
serum starvation.
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Golgi orientation assays
Cells were plated on poly-L lysine (0.01%; Sigma-
Aldrich)-coated coverslips and allowed to reach >80%
confluency. Cells were then transfected with siRNAs for
24 hours and then grown to ≥95% confluency. Cells were
then serum starved (0.5% serum) for 12 hours, wounded
with a sterile 200-ml pipette tip, and then cultured in
complete media (10% serum) for the duration of the
experiment. For cells treated with NSC23766, the inhibi-
tor was added during serum starvation and maintained
throughout the experiment. Cells were then fixed with
3.7% paraformaldehyde (Sigma-Aldrich) for 20 min and
stained for phalloidin, GM130, and 4’,6-diamidino-2-phe-
nylindole (DAPI). Cells were scored as wound oriented if
the majority of the Golgi apparatus was localized in the
third of the cell that faced the wound. Images were
obtained by using a Zeiss Axio 40 CFL with Observer Z1
inverted microscopy and AxioVision software (Carl
Zeiss). All experiments were performed in triplicate.
Immunofluorescence
Cells were plated onto poly-L-lysine-coated coverslips.
They were then fixed with 3.7% paraformaldehyde for
20 min, washed with 1× phosphate-buffered saline
(PBS), and then blocked in 1× PBS containing 3%
bovine serum albumin (Equitech-Bio) and 0.1% Triton
X-100 (J.T. Baker) for 1 hour. After washing with 1×
PBS, cells were incubated with primary antibodies for 1
hour, washed with PBS, and then incubated for 30 min
with secondary antibodies. Where indicated, phalloidin
staining was performed with either Alexa Fluor 488 or
546 (Invitrogen) at a dilution of 1:50 for 20 min. Cells
were viewed with a ZEISS Axiovert 200 M microscope
fitted with an ApoTome Imaging system. Image stacks
in the axial direction were acquired, and all images
shown are from a representative axial plane.
Cellular fractionation
Cell samples were separated out into molar density frac-
tions as described by others [47]. Interfaces between
gradient molarities were obtained and mixed with 2×
SDS loading buffer, boiled, and centrifuged at high
speed before separation of proteins on SDS polyacryla-
mide gels for Western blot analysis.
Statistics
The P values were determined by using a Student’s t
test for nonpaired values. Values are typically given as
mean ± SEM.
Results
Tiam1 is differentially expressed in human breast
epithelial cell lines
To determine whether Tiam1 is expressed in tumor-
derived human breast epithelial cells, lysates were col-
lected from a panel of cell lines and examined with
Western blot with an antibody specific for Tiam1 (Fig-
ure 1). The panel consisted of five tumor cell lines with
different degrees of motility (MDA-MB-231, MDA-MB-
435 S, MDA-MB-453, ZR-75-1, and T-47D), and a
Figure 1 Tiam1 expression correlates with motility, but not Rac activation, in human breast cancer cell lines. (a) Lysates were collected
from a panel of human breast cancer cell lines and examined with Western blot for expression of Tiam1, Vav, Rac1, Cdc42, and a-tubulin
(loading control). Lysates were also examined with affinity precipitation assays for levels of activated Rac1 (Rac1-GTP) and Cdc42 (Cdc42-GTP).
Cell lines are ordered from highest motility on the left to lowest motility on the right. (b) The indicated cell lines were examined with Western
blot by using a Tiam1 antibody (c-16) in the presence (upper panel) or absence (second panel) of blocking peptide, as described in Materials
and Methods. All blots shown are representative of at least three independent experiments.
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nonmotile, nontransformed human breast epithelial cell
line (MCF-10A) (Figure S1 in Additional File 1). The
Tiam1 antibody detects a band at approximately 200
kDa, which is differentially expressed among panel
members (Figure 1a). This band corresponds closely
with the predicted size of full-length Tiam1 and is not
detected when the antibody is used in the presence of a
blocking peptide (Figure 1b). The level of expression of
Tiam1 in this panel is positively correlated with cell
motility. Thus, high expression is observed in the MDA-
MB-231 and MDA-MB-435S cells, modest expression in
the MDA-MB-453 cells, low expression in ZR-75-1 and
T-47 D cells, and no expression is observed in the
MCF-10A cells. For comparison, we also examined the
expression of Vav, a second GEF that predominantly
uses Rac as a substrate. The Vav antibody detects a pre-
dominant band at 130 kDa, which corresponds closely
with the predicted molecular mass of the protein. Unlike
Tiam1, Vav expression is detected at roughly equivalent
levels in all cell lines except T-47 D, in which the
expression is reproducibly low. To demonstrate that dif-
ferences in levels of expression could not be attributed
to uneven loading, the blot was then stripped and
reprobed with an antibody specific for a-tubulin.
Tiam1 expression does not correlate with total Rac
expression and activity
It was previously demonstrated that Tiam1 can activate
Rac1 and Cdc42 in in vitro exchange assays, and Rac1 in
cell-based assays [20]. To determine whether the elevated
levels of Tiam1 that we observed in the more-motile cell
lines is associated with increased levels of activated Rac1,
GST-based affinity precipitation assays were used to
determine the relative levels of GTP-Rac. For compari-
son, levels of activated Cdc42 were also measured. Initi-
ally lysates were collected from the cell lines and
examined for expression of total Rac1 and Cdc42 (Figure
1a). Among panel members, no correlation was observed
between total Rac expression and the expression of
Tiam1 or Vav. All cell lines express both Rac and Cdc42,
with the lowest levels in the highly motile MDA-MB-231
cells and the non-motile MCF-10A cells. Next, we affinity
precipitated GTP•Rac and GTP•Cdc42 from the cell
lysates by using bacterially purified GST-Pak. Surpris-
ingly, no correlation was found between the levels of acti-
vated Rac and Cdc42 and the motility of these cell lines.
Thus, all members of the panel have roughly equivalent
levels of activated Rac, except the highly motile MDA-
MB-231 cells, which have very low levels. A similar pat-
tern is observed for Cdc42, except that activated Cdc42 is
also low in the T-47 D cells. We conclude from this ana-
lysis that (a) high expression levels of a Rac-specific
exchange factor does not necessarily correlate with high
overall Rac activation, and (b) overall levels of activated
Rac and Cdc42 do not necessarily correlate with cell
motility in breast tumor cell lines.
Tiam1 expression is necessary but not sufficient for
motility in breast tumor cells
Because we observed a positive correlation between
motility and Tiam1 expression in our panel of tumor
cell lines, we determined whether Tiam1 supports the
motile phenotype. For this analysis, we used siRNAs tar-
geted at Tiam1 in the MDA-MB-231 and MDA-MB-453
cell lines, both of which express substantial levels of
Tiam1. Recent studies have drawn into question the ori-
gin of the MDA-MB-435S cell line [48,49], so it was not
initially included in this analysis. In the MDA-MB-231
and MDA-MB-453 cell lines, we are able consistently to
suppress the expression of Tiam1 by 80% (Figure 2a)
and 90% (Figure 2c), respectively, and this is associated
with a corresponding reduction in motility in transwell
assays (Figure 2b and 2d). Specific targeting of the 200-
kDa band by the Tiam1-specific siRNAs further con-
firmed the identity of the endogenous protein. Surpris-
ingly, a reduction in Tiam1 expression is not associated
with a significant decrease in overall levels of activated
Rac in either cell line (Figure 2a and 2c). This suggests
that either Tiam1 is regulating only a small fraction of
total Rac activity in these cells, or it is regulating moti-
lity in a Rac-independent manner.
Although our results clearly indicate that Tiam1 is
required for breast cancer cell motility, we also wished
to determine whether it was sufficient to induce a
motile phenotype. For this analysis, we stably expressed
full-length Tiam1, or an activated derivative of Rac1
(Rac1(61L)), in T-47 D cells (Figure 2e). We chose this
cell line because it expresses low levels of endogenous
Tiam1 (Figure 1), and we had previously shown that
overexpression of activated Rac is sufficient to induce a
motile phenotype [50]. Consistent with our previous
results, activated Rac induces a threefold increase in the
motility of these cells in transwell assays (Figure 2f). In
contrast, full-length Tiam1 does not increase endogen-
ous levels of activated Rac (Figure 2e) or the motility
(Figure 2f) of these cells. Overexpression of Tiam1 in a
more-motile cell line (MDA-MB-435S) (Figure S2 in
Additional file 2) did increase endogenous levels of acti-
vated Rac, thus confirming the integrity of the construct.
We conclude that although Tiam1 supports cell move-
ment in highly motile cell lines, overexpression of full-
length Tiam1 is not sufficient to induce cell movement
in a poorly motile cell line.
Tiam1 colocalizes with Golgi markers in breast tumor
cells
Although ectopically expressed Tiam1 is typically
found in the cytoplasm [20,24] or at the leading edge
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of motile cells [24], we determined whether the cellular
distribution of endogenous Tiam1 is different in motile
breast epithelial cells. For this analysis, we used co-
immunofluorescence on the MDA-MB-231, MDA-MB-
453, and T47 D cells by using antibodies for Tiam1
and the Golgi marker, GM130 (Figure 3a). Consistent
with the overexpression studies, a diffuse cytoplasmic
staining of Tiam1 was observed in all three cell lines.
However, strong localized staining also was observed
in the perinuclear region, which corresponds precisely
with the GM130 marker. No staining was observed at
the plasma membrane in any of the three cell types
examined. To confirm that the perinuclear staining
corresponds to an endogenous pool of Tiam1, we then
repeated the immunofluorescence in the MDA-MB-
231 cells in the presence, or absence, of the Tiam1
blocking peptide (Figure 3b). In the presence of the
blocking peptide, no perinuclear staining was observed
in any cells examined.
To confirm that the Tiam1 and GM130 antibodies are
recognizing the Golgi compartment, the co-localization
studies were repeated in the presence or absence of BFA
(Figure 4). In all three cell lines, treatment with BFA
completely disrupted the perinuclear accumulation and
co-localization of both GM130 and Tiam1. To deter-
mine whether the localization of Tiam1 to the Golgi
could account for its contribution to cell motility,
MDA-MB-231 cells were then pretreated for 30 minutes
with BFA, allowed to recover for 3 hours, and then
examined in transwell motility assays. The BFA treat-
ment significantly reduced the motility of the MDA-
MB-231 cells, thus implicating the integrity of the Golgi
in the movement of these cells (Figure 5a). In parallel
cultures, cells were examined for proliferative potential
Figure 2 Tiam1 supports motility in human breast cancer cell lines. MDA-MB-231 (a, b) and MDA-MB-453 (c, d) cells were transfected with
either control siRNAs (si Ctrl) or siRNAs targeting Tiam1 (si Tiam1). (a, c) Lysates were collected at 48 hours and examined with Western blot for
expression of Tiam1, Rac1, and a-actinin (loading control), and with affinity precipitation assays for levels of activated Rac1 (Rac1-GTP). (b, d) Cells
from replicate plates were also examined in transwell motility assays as described in Materials and Methods. Cell migration was quantified at
either 6 hours (MDA-MB-231) or 48 hours (MDA-MB-453). (e) T47 D cell lines were established that stably express full-length (FL) Tiam1, an HA-
epitope tagged, activated derivative of Rac1 (Rac1(61L)), or cognate vector (Ctrl), as described in Materials and Methods. Lysates were collected
and examined with Western blot for expression of total Rac1, Rac1(61L) (HA), and Tiam1, and with affinity precipitation assay for levels of
activated Rac1 (Rac1-GTP). The expression of a-tubulin or a-actinin was also measured as a loading control, as indicated. (f) Cells also were
examined in transwell motility assays. Cell migration was quantified at 24 hours. Data shown are representative of three independently isolated
stable cell lines examined in triplicate experiments (BP).
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(Figure 5b) and by trypan blue exclusion (not shown) to
confirm that the difference in motility could not be
attributed to a decrease in cell growth, or an increase in
cell death. Because of the longer time required to mea-
sure the motility of the MDA-MB-453 cells (24 vs. 3
hours) and the toxicity associated with extended expo-
sure to BFA, an equivalent analysis could not be per-
formed in this cell type.
Localization of Rac to the Golgi of breast epithelial cells
In a previous study using live-cell imaging of polarized,
motile Swiss 3T3 fibroblasts, a small localized pool of
Rac activity was observed in a juxtanuclear region that
was consistent with the endoplasmic reticulum or the
Golgi or both [51]. Thus, we determined whether Rac is
also localized to the Golgi apparatus in MDA-MB-231,
MDA-MB-453, and T-47 D cells. Initially, we performed
immunofluorescence studies, which failed to provide any
definitive evidence for Rac localization to the Golgi in
these cell types (Figure S3 in Additional file 3). Because
our Rac activation assays suggest that Tiam1 is likely to
be regulating only a small pool of Rac, we also per-
formed Golgi fractionations followed by Western blots
by using antibodies for Tiam1 and Rac1 (Figure 6).
RhoA, which is found almost exclusively in the
cytoplasm, was included as a negative control, whereas
GM130 was used as a positive control. As expected
from our immunofluorescence studies, we observed that
a 200-kDa band that is recognized by the Tiam1 anti-
body is present in both the Golgi compartment and in
the cytoplasm in all three cell lines. Similarly, Rac is also
detected in both compartments in all three cell lines.
The purity of the fractionation was confirmed with the
RhoA antibody, which does not cross-react with the
Golgi fraction, and the GM130 antibody, which does
not cross-react with the cytosolic fraction. These results
confirm the presence of both Tiam1 and Rac1 in the
Golgi of human breast epithelial cells.
Tiam1 regulates Golgi reorientation in MDA-MB-231 cells
Directed motility in mammalian cells typically requires
repositioning of the Golgi toward the leading edge [8].
This reorientation can be observed in wound-healing
assays when serum is added to serum-starved cells.
Because Rac1 and Tiam1 are both found in the Golgi of
the MDA-MB-231 and MDA-MB-453 cells, we deter-
mined whether they regulate Golgi reorientation in
these two cell types. Initially we determined whether
Tiam1 supports the motility of these cell lines in a
wound-healing assay. For this analysis, cells were
Figure 3 Endogenous Tiam1 localizes to the Golgi apparatus in breast cancer cells. (a) Cell lines were plated on collagen I (50 μg/ml)-
coated coverslips overnight, and then fixed and stained for Tiam1 (green), GM130 (red; Golgi marker), and DAPI (blue). (b) Localization of
endogenous Tiam1 in MDA-MB-231 cells also was examined in the presence or absence of blocking peptide.
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transfected with control or Tiam1 siRNAs, serum
starved overnight, and then wounded with a pipette tip.
Cells were then fed 10% serum, and migration into the
wound was monitored. Although the MDA-MB-453
cells migrate more slowly into the wound than do the
MDA-MB-231 cells, in both cell lines, substantial
impairment in cell motility is observed when cells are
treated with the Tiam1 siRNAs (Figure 7). This differ-
ence in motility is readily apparent at 12 hours with the
MDA-MB-231 cells and at 24 hours with the MDA-
MB-453 cells.
Next we determined whether impaired motility was
associated with a failure to orient the Golgi toward the
wound (Figure 8). For this analysis, cells were trans-
fected with control siRNAs or Tiam1 siRNAs and then
serum starved overnight. In addition, untransfected cells
were serum starved in the presence of the Rac inhibitor.
Cells were then wounded, and serum was added for 90
minutes (MDA-MB-231) or 210 min (MDA-MB-453) to
induce Golgi re-orientation toward the wound. Cells
were then fixed and stained with a Golgi marker. Cells
at the wound edge were then divided into three equal
sectors, and reorientation of the Golgi into the sector
facing the wound was scored (see Figure 8g for sche-
matic). In cells treated with control siRNAs, approxi-
mately one third of the cells are orientated toward the
Figure 4 Brefeldin A disrupts the cellular distribution of Tiam1. Cells were cultured in the presence (10 μg/ml; BFA+) or absence (BFA-) of
Brefeldin A for 30 minutes under serum-starved conditions. Cells were allowed to recover for an additional 3 hours and were then fixed and
stained for Tiam1 (green), GM130 (red), and DAPI (blue).
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Golgi before serum stimulation, which represents the
expected random probability (the horizontal lines in Fig-
ures 8b, d, and 8f represent this baseline). After serum
stimulation, the percentage of control cells in which the
Golgi is oriented towards the wound increases to
approximately 60% in both cell types (Figure 8b, d, and
8f). In the MDA-MB-231 cells, this reorientation is sub-
stantially reduced if Tiam1 expression is suppressed
(Figure 8b) or Rac1 is inhibited (Figure 8c). In contrast,
Golgi reorientation in the MDA-MB-453 cells appears
to be Tiam1 independent (Figure 8d).
To determine whether the contribution of Tiam1 to
Golgi reorientation is restricted to the MDA-MB-231
cell line, we examined a third tumor cell line that
expresses high levels of Tiam1, MDA-MB-435 S. Like
all other cell lines we examined, Tiam1 is found in the
perinuclear region of these cells, where it co-localizes
with a marker for the Golgi (Figure 9a). Similar to the
MDA-MB-231 cells, suppression of expression of
Tiam1 by siRNA in these cells (Figure 9b) completely
eliminates Golgi reorientation in response to serum
(Figure 9c).
Discussion
Although several reports have indicated that Tiam1 is
overexpressed in breast tumors, the function of Tiam1
in human, tumor-derived breast epithelial cells has not
been determined [23,28]. In this current study, we
observed a positive correlation between Tiam1 expres-
sion and motility in a panel of breast tumor cell lines.
Although Tiam1 has been well characterized as a Rac-
specific GEF [20], we do not observe a correlation
between Tiam1 expression and overall Rac activity, and
reduced expression of Tiam1 does not have an appreci-
able effect on Rac-GTP levels. This suggests that either
Tiam1 is unlinked from Rac in these cell types, or it is
regulating only a small fraction of cellular Rac. Consis-
tent with this latter possibility, we observed that endo-
genous Tiam1 is concentrated in the Golgi complex
Figure 5 Golgi-dependent motility in MDA-MB-231 cells. (a) MDA-MB-231 cells were cultured in the presence (10 μg/ml; BFA+) or absence
(BFA-) of Brefeldin A for 30 minutes under serum-starved conditions. Cells were allowed to recover for an additional 3 hours and then examined
in transwell motility assays, as described in Methods. Cell motility was quantified at 3 hours. (b) In parallel cultures, cells were treated with
Brefeldin A as described earlier, and then equal numbers of cells were plated on collagen. The number of cells was counted at 24 hours and
expressed as a percentage of cells plated. Data shown are an average of three independent experiments.
Figure 6 Tiam1 and Rac1 colocalize to the Golgi apparatus in
human breast cancer cell lines. Golgi and cytosolic fractions were
purified from the indicated cell lines, as described in Materials and
Methods. Fractions were then examined with Western blot for
expression of Tiam1, Rac1, GM130, and RhoA.
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where it co-localizes with a small fraction of the total
cellular Rac. We also observed that at least two other
Rac exchange factors, Vav1 (current study) and Dbl (not
shown), are widely expressed in our panel, which sug-
gests that total Rac activity in breast tumor cells may be
determined by the cumulative activity of multiple Rac-
GEFs. In such a circumstance, the reduced expression of
one RacGEF may not have a discernable effect on total
cellular levels of activated Rac. Our observation that the
suppression of Tiam1 expression can substantially influ-
ence cell motility, without affecting total Rac1 levels,
suggests that GEFs could be used selectively to target
functions of GTPases that support the tumor phenotype,
while avoiding targeting of additional functions that may
be required to support overall cell viability.
Our results indicate that the high level of Tiam1
expression that we observed in MDA-MB-231 and
MDA-MB-453 cells supports the motile phenotype in
both transwell and wound-healing assays. However,
stable expression of full-length Tiam1 in a poorly motile
cell line, such as T-47 D, is not sufficient to induce a
motile phenotype. Although activated Rac is sufficient to
increase the motility of these cells, Tiam1 does not cause
any appreciable increase in Rac-GTP levels when overex-
pressed. Because Tiam1 has a similar cellular distribution
in the highly motile MDA-MB-231, MDA-MB-435 S,
and MDA-MB-453 cells and in the poorly motile T-47 D
cells, its contribution to cell motility may be dependent
on additional activating signals. Consistent with this pos-
sibility, we observed elevated levels of activated Rac1
when we transfected the more-motile MDA-MB-435S
cell line with Tiam1. Like most RhoGEF family members,
Tiam1 contains an amino-terminal autoinhibitory
domain, which must be relieved for it to interact with
and activate its substrate [52]. Many GEF family mem-
bers have been identified based on their transforming
activity in cDNA expression screens, yet in virtually all
cases, the cDNAs are truncated and lack the amino-term-
inal autoinhibitory domain [53]. Because such activating
truncations have not been identified in tumors, the con-
tribution of RhoGEFs such as Tiam1 to tumorigenesis
may be dependent on additional activating signals that
may be present in some cell types, but not in others. For
example, Tiam1 is known to be regulated by direct bind-
ing to activated Ras [54]. Whereas T-47 D cells contain
wild-type copies of all three Ras genes, MDA-MB-231
cells contain an activating mutation in K-Ras, which in
turn may stimulate Tiam1 activity [55]. Similarly, Tiam1
has been shown to be activated in breast epithelial cells
by heregulin 2-mediated signaling [29]. Whereas T-47 D
cells have normal levels of HER2, MDA-MB-453 cells are
HER2-positive [56], which may contribute to Tiam1 acti-
vation in this cell type.
Several studies in other cell types have indicated that
both endogenous and overexpressed Tiam1 is diffusely
localized within the cytoplasm [20,57]. This is consid-
ered to be inactive Tiam1 that will redistribute to mem-
brane ruffles in response to various extracellular signals
[26,58]. For example, with lysophosphatidic acid and
platelet-derived growth factor stimulation of NIH 3T3
cells, serine phosphorylation and membrane transloca-
tion of Tiam1 is observed [58]. Although we have also
Figure 7 Tiam1 supports breast cancer cell motility in wound-healing assays. Plates of confluent MDA-MB-231 and MDA-MB-453 cells were
transfected overnight with 200 nM control (si Ctrl) or Tiam1 (si Tiam1) siRNA. Cells were then examined in a wound-healing assay, as described
in Materials and Methods. Wound closure was measured at 12 hours (MDA-MB-231) or 24 hours (MDA-MB 453). Orange lines indicate the
original wound edges. Images are representative of at least 10 independent locations that were monitored over the length of each wound.
Orange lines indicate original wound edge.
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Figure 8 Golgi reorientation in MDA-MB-231 cells is supported by Tiam1 and Rac1. MDA-MB-231 (a, b, e, f) and MDA-MB-453 (c, d) cells
were examined for serum-dependent Golgi reorientation in a wound-healing assay, as described in Materials and Methods. (a, c) Confluent cells
were transfected with either 200 nM control siRNA (si Ctrl) or Tiam1 siRNA (si Tiam1) overnight, serum starved for 12 hours, and then wounded.
Alternatively, nontransfected cells were serum starved overnight in the presence or absence of 50 μM Rac1 inhibitor (+NSC23766) and were then
wounded (e). After wounding, cells were cultured in 10% serum for 90 minutes (MDA-MB-231) or 210 minutes (MDA-MB-453), and then fixed
and stained for phalloidin (green), GM130 (red), and DAPI (blue). Golgi orientation was then scored. Cells treated with the Rac inhibitor were
maintained on the inhibitor throughout the course of the experiment. a, c, and e show the results of a typical reorientation experiment, with
plus signs indicating cells with Golgi oriented toward the wound, whereas minus signs indicate no orientation. b, d, and f show quantification of
three independent experiments. (g) Schematic showing the method of scoring of the reorientation experiments.
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observed that Tiam1 is localized within the cytoplasm in
MDA-MB-231, MDA-MB-453, MDA-MB-435 S, and T-
47 D cell lines, we did not observe any accumulation of
Tiam1 at the plasma membrane, or within lamellipodia
or membrane ruffles. This is particularly apparent in the
MDA-MB-231 cells, which have a striking mesenchymal
morphology with numerous membrane protrusions.
However, we observed a strong perinuclear accumula-
tion of Tiam1 in all four cell lines that coincides with a
marker for the Golgi, and cellular fractionations con-
firmed that Tiam1 is associated with this organelle.
Treatment of the MDA-MB-231 cells with BFA dis-
rupted the association of Tiam1 with the Golgi and
reduced cell motility, suggesting that this association
could account for the contribution of Tiam1 to cell
motility. Although the BFA treatment had a weaker
effect on cell motility than Tiam1 siRNAs, this is likely
because the BFA treatments used in our analysis were
mild, and of very short duration, to avoid the toxicity
normally associated with this compound. To our knowl-
edge, this represents the first demonstration of Golgi
localization for endogenous Tiam1 and suggests that it
may play a role in cell motility that has not been pre-
viously appreciated.
Unlike endogenous Cdc42, which is predominantly
localized to the Golgi in mammalian cells [59-61], the
localization and activity of Rac in the Golgi is less clear.
Antibodies for endogenous Rac typically do not strongly
stain the Golgi, and we did not observe such staining in
the MDA-MB-231, MDA-MB-453, and T-47 D cells.
However, by using live-cell imaging of polarized, motile
Swiss 3T3 fibroblasts, Rac activity was observed in a jux-
tanuclear region that was consistent with the ER or the
Golgi [51]. This suggests that the Golgi may contain a
small fraction of cellular Rac, which is required to sup-
port the motile phenotype. Consistent with this possibi-
lity, we used fractionations to confirm that Rac is in the
Golgi of MDA-MB-231, MDA-MD-453, and T-47 D
cells, and thus may be the target for Tiam1 in this orga-
nelle. Because this probably represents a small fraction
of the total cellular Rac in these cells, this could account
for why we did not observe substantive changes in over-
all Rac activity when Tiam1 expression was suppressed
in these cell lines.
Consistent with a role for Tiam1 in the Golgi, we
observed that MDA-MB-231 and MDA-MB-435S cells do
not efficiently polarize their Golgi in a wound-healing
assay if Tiam1 expression is suppressed or Rac1 is inhib-
ited (MDA-MB-231 cells). Although these cells are still
able to migrate into the wound, they do so less efficiently,
which likely reflects the lack of polarization. Thus, Tiam1
may be required for polarization, but not cell movement
per se. The molecular mechanisms that regulate Golgi
reorientation during the directed migration of tumor cells
is unclear but may involve localized remodeling of the
actin cytoskeleton. Both actin and actin-binding proteins
Figure 9 Golgi reorientation in MDA-MB-435S cells is supported by Tiam1. (a) MDA-MB-435S cells were plated on collagen I (50 μg/ml)-
coated coverslips overnight, and then fixed and stained for Tiam1 (green), GM130 (red; Golgi marker), and DAPI (blue). (b) Confluent cells were
transfected with either 200 nM control siRNA (si Ctrl) or Tiam1 siRNA (si Tiam1) overnight and then examined with Western blot for suppression
of Tiam1 expression. (c) Cells from parallel cultures were then serum starved for 12 hours, wounded, and examined for serum-dependent Golgi
reorientation, as described in Materials and Methods. Quantification is shown for three independent experiments.
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have been localized to the Golgi [62], and actin-depolymer-
izing drugs have been shown to disrupt Golgi morphology
and positioning [63-65]. In HEK and COS7 cells, a fraction
of Rac has been shown to co-localize with the RacGAP,
OCRL1, and g-adaptin in the trans-Golgi network, which
suggests a role for Rac, and possibly Tiam1, in the secre-
tory pathway [66]. In migrating keratinocytes, Tiam1
associates with the Par complex at the leading edge to pro-
mote the stabilization of the microtubule network [24].
Although we have not detected Tiam1 at the leading edge
of MDA-MB-231 cells, it may function in the Golgi to
facilitate reorientation of the microtubule-organizing appa-
ratus and stabilization of microtubules directed toward the
leading edge.
Although loss of Tiam1 expression had a profound
effect on Golgi reorientation in MDA-MB-231 and
MDA-MB-435S cells, it does not appear to support
reorientation in MDA-MB-453 cells. This suggests that
breast tumor cell lines regulate Golgi reorientation
through distinct mechanisms and that Tiam1 can regu-
late multiple aspects of the motile phenotype. With
regard to Golgi reorientation, recent studies in fibro-
blasts suggest that cell-specific diversity may occur in
this process, and that Golgi reorientation may have a
different function in slow-moving cells when compared
with faster-moving cells [67]. In this regard, it is of note
that the MDA-MB-231 and MDA-MB-435S cells are
more motile than the MDA-MB-453 cells and have a
strikingly different morphology. Thus, the MDA-MB-
231 and MDA-MB-435S cells are elongated and
mesenchymal in morphology, with many cells exhibiting
an easily recognizable leading edge, whereas the MDA-
MB-453 cells are rounded and epithelium-like and do
not exhibit polarized structures in culture.
Conclusions
In summary, our studies show that Tiam1 expression
correlates with motility in human breast cancer cell
lines and is required to support the motile phenotype.
Moreover, we demonstrated that endogenous Tiam1 is
localized to the Golgi apparatus in breast tumor cells,
where it regulates at least one Golgi function that is
required to support motility. Because Tiam1 supports
motility in breast tumor cells without any substantial
effect on total cellular Rac-GTP levels, it may represent
an attractive target for therapeutic intervention.
Additional material
Additional file 1: Supplementary Figure 1. Relative motility of
breast cancer cell lines. The indicated cell lines were examined in
transwell motility assays, as described in Materials and Methods. Data
shown are the average of three independent experiments performed in
triplicate wells.
Additional file 2: Supplementary Figure 2. Overexpression of full-
length Tiam1 increases Rac activity in MDA-MB-435S cells. MDA-MB-
435S cells were transiently transfected with full-length (FL) Tiam1, an HA-
epitope tagged, activated derivative of Rac1 (Rac61L), or cognate vector
(Vector). Lysates were collected and examined with Western blot for
expression of total Rac1, Rac61L (HA), and Tiam1, and with affinity
precipitation assay for levels of activated Rac1 (Rac1 GTP). The expression
of a-tubulin was also measured as a loading control, as indicated. Data
shown are representative of three independent experiments.
Additional file 3: Supplementary Figure 3. Endogenous Rac1 does
not significantly colocalize with a Golgi marker in breast cancer
cells. Cell lines were plated on collagen I (50 μg/ml)-coated coverslips
overnight, and then fixed and stained for Rac1 (green), GM130 (red), and
DAPI (blue).
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